Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Cellectis S.A. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 40 | 34 | −6 |
| Shares | 8.73M | 15.2M | +6.47M (+74.1%) |
| Value | $18.3M | $29.3M | +$11.0M (+59.7%) |
New holders (6)
Institutions that held Cellectis S.A. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bpifrance SA | 2,186,960 | $4.22M | 0.11% |
| CVI Holdings, LLC | 129,434 | $249.8K | 0.09% |
| LPL Financial LLC | 12,357 | $23.8K | 0.00% |
| One68 Global Capital, LLC | 11,000 | $21.2K | 0.03% |
| EverSource Wealth Advisors, LLC | 13 | $25 | 0.00% |
| Toronto Dominion Bank | 31 | $0 | 0.00% |
Sold out (12)
Institutions that held Cellectis S.A. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Capital World Investors | 250,000 | $525.0K |
| Citadel Advisors LLC | 58,207 | $122.2K |
| Susquehanna International Group, LLP | 58,087 | $122.0K |
| Tower Research Capital LLC (TRC) | 26,362 | $56.0K |
| Ergoteles LLC | 19,365 | $40.7K |
| Goldman Sachs Group Inc | 18,208 | $38.2K |
| Money Concepts Capital Corp | 515 | $1.08K |
| Citigroup Inc | 263 | $552 |
| BNP Paribas Arbitrage, SA | 166 | $349 |
| Parkside Financial Bank & Trust | 147 | $309 |
| US Bancorp | 10 | $21 |
| FMR LLC | 9 | $19 |